Understanding, recognizing, and managing toxicities of targeted anticancer therapies
Understanding, recognizing, and managing toxicities of targeted anticancer therapies
复制标题
DOI：
10.3322/caac.21184
复制
发表时间：
2013-07-01
影响因子：
254.7
通讯作者：
Adjei, Alex A.
中科院分区：
文献类型：
--
作者：
Dy, Grace K.;Adjei, Alex A.
回答问题并获得 CME/CNE 基因组学和分子生物学的进步已经确定了癌细胞中的异常蛋白质，这些蛋白质是癌症治疗的有吸引力的靶点。由于与正常细胞相比，这些蛋白质在癌细胞中过度表达或失调，因此推测它们的抑制剂将具有狭窄的靶向性并且相对无毒。然而，这个希望并没有实现。目前的靶向药物与传统细胞毒性药物表现出相同的毒性频率和严重程度，主要区别在于毒性作用的性质。因此，脱发、骨髓抑制、粘膜炎、恶心和呕吐等经典化疗毒性通常已被血管、皮肤、内分泌、凝血、免疫、眼和肺毒性所取代。需要认识、预防和最佳管理这些毒性。加州癌症临床杂志 2013 年；63：249-279。 ((c))2013 美国癌症协会
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins are overexpressed or dysregulated in cancer cells compared with normal cells, it was assumed that their inhibitors will be narrowly targeted and relatively nontoxic. However, this hope has not been achieved. Current targeted agents exhibit the same frequency and severity of toxicities as traditional cytotoxic agents, with the main difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities of alopecia, myelosuppression, mucositis, nausea, and vomiting have been generally replaced by vascular, dermatologic, endocrine, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed. CA Cancer J Clin 2013;63:249-279. ((c))2013 American Cancer Society, Inc.